| CAS NO: | 120092-65-1 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 120092-65-1 |
| Canonical SMILES | OC(C1CCCCC1)(C(OCC#CCN(C([2H])([2H])C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])[2H])=O)C2=CC=CC=C2.Cl |
| 分子式 | C22H21D10NO3.HCl |
| 分子量 | 404 |
| 溶解度 | Chloroform: Slightly Soluble,DMSO: Slightly Soluble,Methanol: Slightly Soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Oxybutynin-d10is intended for use as an internal standard for the quantification of oxybutynin by GC- or LC-MS. Oxybutynin is an antagonist of muscarinic acetylcholine receptors (Kis = 5, 14.5, 3.7, 5.3, and 40 nM for human recombinant M1-5, respectively).1It inhibits intracellular calcium mobilization induced by carbamoylcholine in bladder smooth muscle and submandibular gland cells isolated from cynomolgus monkeys (Kis = 2 and 1 nM, respectively).2Oxybutynin inhibits volume-induced bladder contraction (VIBC) and oxotremorine-induced salivation (OIS) in rats (ID50s = 0.062 and 0.089 mg/kg, respectively).1It also increases pupil diameter (PD) and locomotor activity (LMA; ED50s = 0.29 and 0.52 mg/kg, respectively) and decreases small intestinal transit (SIT; ID50= 0.22 mg/kg) in rats. Formulations containing oxybutynin have been used in the treatment of overactive bladder. 1.McNamara, A., Pulido-Rios, M.T., Sweazey, S., et al.Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonistEur. J. Pharmacol.605(1-3)145-152(2009) 2.Kobayashi, S., Ikeda, K., and Miyata, K.Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: A Ca2+ mobilization study in monkey cellsLife Sci.74(7)843-853(2004) |
m.cnreagent.com